Entries by Thomas Gabrielczyk

MGI turns a new page in the human genome era with ultra-high throughout DNBSEQ-T7 sequencer*

Amidst the rapid evolution of DNA sequencing technologies in past years, the industry has been working tirelessly to make genomics more accessible. Since the Human Genome Project, which saw scientists from six countries coming together to map the first human genome at nearly $3 billion over 13 years, the cost of whole-genome sequencing has fallen to less than $1,000 today. Yet, the quest to produce larger amounts of short- and long-read data in a shorter span of time and at an even lower cost continues.

Anti-ID antibody production

An anti-idiotypic anti­body (anti-ID Ab) can recognise and bind to the idiotypic center of another antibody. Anti-idiotype antibodies are widely used in therapeutic drug development, such as immunogenicity assessments, pharmacokinetic/pharmacodynamics (PK/PD) studies, and vaccine development.

Avantium gets EU grant

Avantium NV will get a €3m EU funding for a feasibility study of the electrochemical conversion of CO2 to consumer products.